Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 6 Plasma cholesterol and triacylglycerol in minipigs treated with G. lucidum and lovastatin (mmol/L)

From: Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs

Group TC TC TC TC TAG TAG TAG TAG VLDL VLDL LDL LDL HDL HDL LDL/HDL LDL/HDL
  D1 D14 D21 D29 D1 D14 D21 D29 D14 D29 D14 D29 D14 D29 D14 D29
Gl (2.5%) 2.47a 3.21bc 2.81 2.58 0.53 0.57 0.80 0.69 0.07 0.09 1.45c 1.08 1.69c 1.42 0.88 0.79
Lovastatin 2.36a 3.00 2.44 2.81 0.50 0.60 0.59 0.71 0.10 0.09 1.40 1.29 1.50 1.43 0.95 0.91
  1. Lovastatin was administered at 80 mg/d. Between D1-14, all pigs received a high cholesterol and fat control diet; from D15-29, pigs received either G. lucidum (Gl) extract or lovastatin. The same statistical conclusions were reached if all 10 pigs were compared between D1-14. Pigs were randomly selected to receive either GI or lovastatin before study commencement. Student's, paired, 1-tailed, t-test, was utilized for statistical comparisons. Statistically significant changes (P < 0.05, 1-tailed testing) in cholesterol parameters are indicated as follows: aD1 vs. 14; bD14 vs. 21; cD14 vs. 29. Abbreviations: refer to Table 3. There was a slight trend for 2.5% Gl to reduce LDL/HDL ratio between D14-29 (P < 0.11, 1-tailed testing).